Importantly, we found that patients with a planned heart valve intervention, such as TAVR, and especially M/T-TEER, are at very high risk of clinically progredient CHF during the prolonged waiting time, as measured by NT-proBNP levels in combination with worsening of clinical symptoms, including dyspnea as assessed by NYHA class, emergency cardiovascular hospitalization, and decline of LVEF. Here, NPPB is linked to congestive heart failure.